🎉 M&A multiples are live!
Check it out!

Kyverna Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Kyverna Therapeutics and similar public comparables like Vivoryon Therapeutics, Galapagos, and Benevolent AI.

Kyverna Therapeutics Overview

About Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.


Founded

2018

HQ

United States of America
Employees

112

Website

kyvernatx.com

Financials

LTM Revenue n/a

LTM EBITDA -$156M

EV

-$181M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Kyverna Therapeutics Financials

Kyverna Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$156M.

In the most recent fiscal year, Kyverna Therapeutics achieved revenue of n/a and an EBITDA of -$125M.

Kyverna Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Kyverna Therapeutics valuation multiples based on analyst estimates

Kyverna Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$58.5M -$125M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$28.9M -$60.4M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Kyverna Therapeutics Stock Performance

As of April 15, 2025, Kyverna Therapeutics's stock price is $2.

Kyverna Therapeutics has current market cap of $96.4M, and EV of -$181M.

See Kyverna Therapeutics trading valuation data

Kyverna Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$181M $96.4M XXX XXX XXX XXX $-3.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Kyverna Therapeutics Valuation Multiples

As of April 15, 2025, Kyverna Therapeutics has market cap of $96.4M and EV of -$181M.

Kyverna Therapeutics's trades at n/a LTM EV/Revenue multiple, and 1.2x LTM EBITDA.

Analysts estimate Kyverna Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Kyverna Therapeutics and 10K+ public comps

Kyverna Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$181M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.4x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Kyverna Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Kyverna Therapeutics Valuation Multiples

Kyverna Therapeutics's NTM/LTM revenue growth is n/a

Kyverna Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Kyverna Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Kyverna Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Kyverna Therapeutics and other 10K+ public comps

Kyverna Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 114% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Kyverna Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Kyverna Therapeutics M&A and Investment Activity

Kyverna Therapeutics acquired  XXX companies to date.

Last acquisition by Kyverna Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Kyverna Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Kyverna Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Kyverna Therapeutics

When was Kyverna Therapeutics founded? Kyverna Therapeutics was founded in 2018.
Where is Kyverna Therapeutics headquartered? Kyverna Therapeutics is headquartered in United States of America.
How many employees does Kyverna Therapeutics have? As of today, Kyverna Therapeutics has 112 employees.
Who is the CEO of Kyverna Therapeutics? Kyverna Therapeutics's CEO is Mr. Warner Weston Biddle.
Is Kyverna Therapeutics publicy listed? Yes, Kyverna Therapeutics is a public company listed on NAS.
What is the stock symbol of Kyverna Therapeutics? Kyverna Therapeutics trades under KYTX ticker.
When did Kyverna Therapeutics go public? Kyverna Therapeutics went public in 2024.
Who are competitors of Kyverna Therapeutics? Similar companies to Kyverna Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Kyverna Therapeutics? Kyverna Therapeutics's current market cap is $96.4M
What is the current EBITDA of Kyverna Therapeutics? Kyverna Therapeutics's last 12-month EBITDA is -$156M.
What is the current EV/EBITDA multiple of Kyverna Therapeutics? Current EBITDA multiple of Kyverna Therapeutics is 1.2x.
Is Kyverna Therapeutics profitable? Yes, Kyverna Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.